What is HC Wainwright’s Forecast for ALGS FY2024 Earnings?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – HC Wainwright lifted their FY2024 earnings estimates for Aligos Therapeutics in a research report issued on Thursday, November 7th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings of ($9.21) per share for the year, up from their previous forecast of ($11.21). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($9.82) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q4 2024 earnings at ($1.83) EPS, Q1 2025 earnings at ($1.85) EPS, Q2 2025 earnings at ($1.95) EPS, Q3 2025 earnings at ($2.13) EPS, Q4 2025 earnings at ($2.19) EPS, FY2025 earnings at ($8.13) EPS, FY2026 earnings at ($6.82) EPS, FY2027 earnings at ($7.57) EPS and FY2028 earnings at ($7.26) EPS.

Aligos Therapeutics Stock Performance

Shares of NASDAQ:ALGS opened at $17.85 on Monday. The stock has a market capitalization of $57.12 million, a price-to-earnings ratio of -1.12 and a beta of 2.11. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $30.00. The company’s fifty day moving average is $9.83 and its two-hundred day moving average is $12.47.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The company had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. During the same quarter last year, the company earned ($10.25) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC boosted its position in Aligos Therapeutics by 17.6% during the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after acquiring an additional 98,628 shares during the period. Opaleye Management Inc. lifted its holdings in shares of Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after purchasing an additional 333,000 shares in the last quarter. Finally, Armistice Capital LLC lifted its holdings in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).